Key regions: India, Japan, France, Brazil, South Korea
The Anti-Fibrinolytic Drugs market in Southern Asia has been steadily growing over the years.
Customer preferences: One of the main reasons for the growth in this market is the increasing prevalence of bleeding disorders in the region. Patients suffering from conditions such as hemophilia and von Willebrand disease require Anti-Fibrinolytic Drugs to prevent excessive bleeding. Moreover, the rise in geriatric population and the increasing number of surgeries being performed in the region have also contributed to the growth of the market.
Trends in the market: India has emerged as one of the largest markets for Anti-Fibrinolytic Drugs in Southern Asia. The country has a high prevalence of bleeding disorders and a large patient population. In addition, the government has taken several initiatives to improve healthcare infrastructure in the country, which has led to an increase in the number of surgeries being performed. This has further boosted the demand for Anti-Fibrinolytic Drugs in the country.
Local special circumstances: Pakistan and Bangladesh are also emerging markets for Anti-Fibrinolytic Drugs. The healthcare infrastructure in these countries is improving, and there is a growing awareness among patients about the availability of these drugs. However, the market in these countries is still largely untapped, and there is a need for more investment in healthcare infrastructure.
Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in Southern Asia can also be attributed to the overall economic development of the region. As the economies of countries in the region continue to grow, there is an increase in disposable income, which has led to a rise in healthcare spending. In addition, the increasing penetration of health insurance in the region has made healthcare more accessible to the general population.In conclusion, the Anti-Fibrinolytic Drugs market in Southern Asia is expected to continue growing in the coming years, driven by the increasing prevalence of bleeding disorders, rising geriatric population, and improving healthcare infrastructure. Countries such as India, Pakistan, and Bangladesh are expected to be key markets for Anti-Fibrinolytic Drugs in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
